TOP TEN perturbations for 1021_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1021_at
Selected probe(set): 210354_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1021_at (210354_at) across 6537 perturbations tested by GENEVESTIGATOR:

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):7.7177277
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):7.5066547
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):6.961401
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):6.16255
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):5.935293
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

dendritic cell study 7 (IL-4 mddc) / dendritic cell study 7 (IL-15 mddc)

Relative Expression (log2-ratio):-5.7378054
Number of Samples:3 / 3
Experimental dendritic cell study 7 (IL-4 mddc)
Mature IL-4 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Monocytes were cultured with 800 IU/mL granulocyte macrophage colony-stimulating factor and 20 ng/mL IL-4 in order to generate immature IL-4 DCs. Conventional maturation cocktail, comprising 10 ng/mL tumor necrosis factor-α, 10 ng/mL interleukin-1β, 15 ng/ml interleukin-6 and 1 µg/mL prostaglandin E2 was added for 48 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.
Control dendritic cell study 7 (IL-15 mddc)
Mature IL-15 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Differentiation was induced with 800 IU/mL granulocyte macrophage colony-stimulating factor and 200 ng/mL IL-15 to obtain immature IL-15 DCs. A TLR-activating maturation cocktail, comprising 3 µg/mL R848, 2.5 ng/mL tumor necrosis factor-α, 250 ng/mL interferon-γ and 1 µg/mL prostaglandin E2 was added after 24-48 hours of differentiation for 18-20 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.

VTX-2337 study 1 / 3M-055 study 1

Relative Expression (log2-ratio):5.733691
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control 3M-055 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):5.6894255
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

VTX-2337 study 1 / untreated monocyte sample

Relative Expression (log2-ratio):5.661874
Number of Samples:3 / 3
Experimental VTX-2337 study 1
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control untreated monocyte sample
Peripheral blood monocytes isolated from healthy donors.

E. coli study 1 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):5.5062504
Number of Samples:12 / 16
Experimental E. coli study 1
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.